Engineered immune cells take aim at Hard-to-Treat cancers
NCT ID NCT03745326
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This early-phase trial tested a new treatment for people with advanced cancers (like pancreatic, stomach, or colon cancer) that have a specific genetic change called KRAS G12D. Doctors took participants' own white blood cells, modified them in a lab to better recognize and attack cancer cells, and then infused them back. The goal was to see if this approach is safe and can shrink tumors. Only 5 people took part, and the study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.